Edward White is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on both the biotechnology and the specialty pharmaceutical sectors. Mr. White’s expertise covers companies operating in the oncology, immune-oncology, infectious disease, and gastrointestinal sectors. Prior to working at H.C. Wainwright, Mr. White has worked as a Wall Street Healthcare Analyst, on both the buy-side and the sell-side, since 1996. Mr. White’s previous sell-side experience includes working for Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms.
At Deutsche Bank, he worked on two Institutional Investor ranked analyst teams. Most recently, Mr. White worked as a Senior Biotech Analyst at FBR & Company. On the buy-side, Mr. White worked as a Senior U.S. Healthcare Analyst for Mitsubishi UFJ Trust and Banking where he was a member of a team that managed a fund that had its peak at over $16 billion, including $10 billion in U.S. equities. Mr. White’s educational background includes an MBA from Rensselaer Polytechnic Institute as well as a B.S. in Biology from Manhattan College. Mr. White also attended the Mount Sinai School of Medicine for two and a half years. Mr. White was recently recognized as the top Biotech Analyst in the 2017 Thompson/Reuters Survey for earnings estimate accuracy.
